Funder: American Cancer Society
Due Dates: November 24, 2026 (ACS budget/U.S. materials) | December 4, 2026 (Full application to CRUK)
Funding Amounts: UK: £100,000–£600,000; U.S.: up to $946,000 including indirect costs; 1–5 years
Summary: Supports collaborative UK–U.S. research translating biological insights into approaches for primary cancer prevention.
Key Information: CRUK must confirm scientific remit, and ACS must approve the U.S. budget before full submission.
Description
The American Cancer Society (ACS) and Cancer Research UK (CRUK) jointly support well-defined, discrete projects that harness biological and mechanistic insights to develop targets and approaches for primary cancer prevention. The award supports hypothesis-driven translational research with a clear path toward reducing cancer risk or incidence, from exploratory pilot studies through early clinical experimentation. Immediate prevention impact within the award period is not required, but applicants must explain the subsequent research needed to achieve it.
Projects must be genuine scientific partnerships, with complementary but distinct expertise and integrated work across UK and U.S. teams. Suitable work includes validating prevention targets, developing preventive interventions, modulating precancerous lesions, applying risk stratification, understanding modifiable risk factors, repurposing drugs or dietary compounds, and validating biomarkers or surrogate endpoints. New collaborations are encouraged alongside productive existing partnerships.
